![European American Chamber of Commerce New York [EACCNY] | Your Partner for Transatlantic Business Resources](https://eaccny.com/wp-content/uploads/2020/06/eaccny-logo.png){kind=logo}
Belgian biopharmaceutical pioneer and EACCNY premium member Flen Health has achieved a critical regulatory milestone in its expansion into the United States healthcare market.
The company announced a successful pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) for its highly anticipated topical drug candidate, VES gel.
The advanced, enzyme-based formulation is designed specifically to treat chronic diabetic foot ulcers, a widespread and severe medical condition that currently lacks highly effective, rapid-healing therapeutic options. Following positive alignment with federal regulators, Flen Health has officially advanced the treatment into its “AIM-DFU” clinical trials, successfully enrolling its first patient.
This major milestone brings the specialized pharmaceutical firm significantly closer to achieving full U.S. registration. If approved, VES gel is positioned to capture a substantial share of the multi-billion dollar American wound-care market, offering patients and healthcare providers a vital new tool to accelerate healing, prevent infections, and reduce long-term amputation risks.